Vitro, leading biotechnology company in integrated in vitro diagnostic solutions (IVD) for cancer treatment, y Getronics, leading multinational in technological services with more than 135 years of international experience, have reached a strategic alliance with the objective of promoting the expansion of Anapath in the health market and providing a first-level support and implementation service to Pathological Anatomy services..
Anapath is the laboratory management software (LIMs) of Pathological Anatomy developed entirely by Vitro, which is the leader in the Spanish market, and is among the most advanced systems globally to accompany the digital transformation of Pathological Anatomy laboratories towards computational pathology.
This agreement will allow Getronics to assume leadership in the direct sales operation, support and implementation of Vitro pathology laboratory management solutions, consolidating an agile collaboration model, specialized and oriented to sustainable growth.
The alliance is part of the development and operational efficiency plan launched by Vitro on a global scale, in line with other collaborations already active. This strategic synergy will allow scaling the capacity to provide a highly specialized service, guaranteeing operational continuity with the highest quality standards, while reinforcing the closeness, specialization and flexibility that our clients demand.
Getronics, with presence in more than 20 countries and more 4.000 professionals, provides a robust structure, a vision focused on the end user and deep experience in managing IT infrastructures and services. Its incorporation as a strategic partner responds to Vitro's vision of the future for Anapath: offer high-value diagnostic and data management solutions with agile implementation, efficient and close to the patient.
With this alliance, Vitro and Getronics reinforce their position as a reference technological partner for health authorities, hospitals and laboratories, moving towards a more scalable operating model, specialized and prepared for the global challenges of cancer diagnosis.
